Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

By A. Parsa, J. Waldron, Amith Panner, C. Crane, I. Parney, J. Barry, Kristine E Cachola, Joseph C. Murray, T. Tihan, M. Jensen and 3 more. Nature Medicine, 2007

1,358 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/9b9f97af6fd04142afc92e18f038201d8af19cef

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors (2013, background): “While PTEN loss has been associated with increased PDL1 expression in gliomas (8), it is unknown whether specific genomic subsets of lung tumors utilize the PD-1 pathway as a mechanism of immune escape.”
The blockade of immune checkpoints in cancer immunotherapy (2012, background): “The expression on glioblastomas is enhanced on deletion or silencing of PTEN , which implicates the involvement of the PI3K–AKT pathwa”
Inhibitory B7-family molecules in the tumour microenvironment (2008, background): “A recent study indicates that the phosphatase and tensin homologue (PTEN)–phosphatidylinositol-3-kinase pathway might be important in the post-transcriptional regulation of B7-H1 cell-surface expression in tumour”
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. (2016, background): “PTEN loss or PIK3CA mutations in glioma, breast, and prostate cancers have been shown to activate the AKT–mTOR pathway and subsequently increase PD-L1 expression (14, 15).”
Classifying cancers based on T cell infiltration and PD-L1 (2015, positive): “PD-L1 can also be expressed constitutively on cancer cells through poorly characterized oncogenic signaling pathways (21, 22).”
Targeting PI3K/Akt signal transduction for cancer therapy (2021, background): “Studies have shown that the activation of the Akt signaling pathway caused by the deletion of PI3KCA mutations is strongly related to the upregulation of PD-L1 expression in the prostate gland.(145) In mouse lung cancer models and human lung cancer cell lines, the Akt signaling pathway regulates the”
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas (2013, positive): “Programmed-death-1 (PD-1, CD279), an immune checkpoint surface receptor expressed on lymphocytes, has been implicated as a mediator of immune suppression in a variety of tumors, including GBM (3).”
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014, neutral): “000 Present 6 (15) 5 (83) 1 (17) 4 (67) 2 (33) Necrosis (n 1⁄4 41) Absent 27 (66) 19 (70) 8 (30) 0.”
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma (2013, background): “For example, PD-L1 expression has been reported to increase with phosphoinositide-3- kinase (PI3K)/AKT pathway activation due to loss of PTEN function in glioblastoma cells (17).”
The PD-1 Pathway in Tolerance and Autoimmunity (2010, background): “tional PD-L1 expression in cancers (40).”
Mechanisms controlling PD-L1 expression in cancer (2019, background): “Besides maintaining the stability of PD-L1 mRNA, PD-L1 expression can be upregulated by accelerating protein synthesis under the loss of PTEN in tumor cells, which leads to activation of the Akt/mTOR/S6K1 pathway and elevated PD-L1 protein translation rate as reported for glioma (Parsa et al., 2007)”
PD-L1 Expression in Triple Negative Breast Cancer (2014, positive): “Expression of PD-L1 on glioblastomas is increased by the deletion or silencing of PTEN, implicating involvement of the phosphoinositide 3-kinase (PI3K) pathway (15).”